Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 1/20 | 0.36 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17052659 | 1.00 | TLR4 (0.36) | TLR4LY96CYP2C19HIF1ASMPD1 | |
| SCHEMBL27282032 | 0.84 | SMPD1 (0.36) | SMPD1 | |
| SCHEMBL17052660 | 0.83 | — | — | |
| SCHEMBL1104569 | 0.81 | SMPD1 (0.45) | SMPD1 | |
| SCHEMBL25976119 | 0.80 | TLR4 (0.39) | TLR4LY96CYP2C19HIF1ASMPD1 | |
| SCHEMBL17052655 | 0.80 | TLR4 (0.39) | TLR4LY96CYP2C19HIF1ASMPD1 | |
| SCHEMBL13633940 | 0.78 | — | — | |
| SCHEMBL12149515 | 0.77 | LGALS8 (0.31) | — | |
| SCHEMBL19940051 | 0.75 | — | — | |
| SCHEMBL25572011 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230256112-A1 | ANTI-TRANSFERRIN RECEPTOR (TFR) ANTIBODY AND USES THEREOF | Dyne Therapeutics, lnc. (US) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230256112-A1 | ANTI-TRANSFERRIN RECEPTOR (TFR) ANTIBODY AND USES THEREOF | TFRC, FTH1, FOLR1 | TLR4 1416/4885LY96 41/4885CYP2C19 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.